Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.
Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, Francis RJ, Zhang AY, Scott AM, Lee ST, Azad AA, McJannett MM, Stockler MR, Williams SG, Davis ID, Hofman MS; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Buteau JP, et al. Lancet Oncol. 2022 Nov;23(11):1389-1397. doi: 10.1016/S1470-2045(22)00605-2. Epub 2022 Oct 16. Lancet Oncol. 2022. PMID: 36261050 Clinical Trial.
The evolving definition of bulky disease for lymphoma.
Buteau JP, Seymour JF, Hofman MS. Buteau JP, et al. Leuk Lymphoma. 2020 Jul;61(7):1525-1528. doi: 10.1080/10428194.2020.1797014. Epub 2020 Jul 20. Leuk Lymphoma. 2020. PMID: 32684049 No abstract available.
The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study.
Emmett L, Buteau J, Papa N, Moon D, Thompson J, Roberts MJ, Rasiah K, Pattison DA, Yaxley J, Thomas P, Hutton AC, Agrawal S, Amin A, Blazevski A, Chalasani V, Ho B, Nguyen A, Liu V, Lee J, Sheehan-Dare G, Kooner R, Coughlin G, Chan L, Cusick T, Namdarian B, Kapoor J, Alghazo O, Woo HH, Lawrentschuk N, Murphy D, Hofman MS, Stricker P. Emmett L, et al. Eur Urol. 2021 Dec;80(6):682-689. doi: 10.1016/j.eururo.2021.08.002. Epub 2021 Aug 28. Eur Urol. 2021. PMID: 34465492
Radiation Dosimetry in 177Lu-PSMA-617 Therapy.
Jackson P, Hofman M, McIntosh L, Buteau JP, Ravi Kumar A. Jackson P, et al. Among authors: buteau jp. Semin Nucl Med. 2022 Mar;52(2):243-254. doi: 10.1053/j.semnuclmed.2021.11.003. Epub 2021 Dec 8. Semin Nucl Med. 2022. PMID: 34893320 Review.
High prostate-specific membrane antigen (PSMA) positron emission tomography (PET) maximum standardized uptake value in men with PI-RADS score 4 or 5 confers a high probability of significant prostate cancer.
Ptasznik G, Papa N, Kelly BD, Thompson J, Stricker P, Roberts MJ, Hofman MS, Buteau J, Murphy DG, Emmett L, Moon D. Ptasznik G, et al. BJU Int. 2022 Nov;130 Suppl 3(Suppl 3):5-7. doi: 10.1111/bju.15736. Epub 2022 Apr 20. BJU Int. 2022. PMID: 35362659 Free PMC article. No abstract available.
35 results